MRI outperforms hybrids for bone tumor screening
A preliminary trial at University Hospitals Munich has established MRI's ascendancy for 32 patients. Thirteen received whole-body MRI and FDG-PET/CT to diagnose suspected bone metastases from primary breast cancers. Six had a gastrointestinal tumor, and another six had cancers with an unknown primary origin. Other patients were diagnosed with lymphoma, hepatocellular carcinoma, sarcoma, or melanoma.
Whole-body MRI and FDG-PET/CT showed 91% and 78% accuracy, respectively, in identifying 127 bone lesions. MRI's sensitivity of 94% was significantly better than PET/CT's 78%. Although PET/CT was more specific (80% versus 76%), the difference was not significant, said chief investigator Dr. Gerwin P. Schmidt.
The superior performance of whole-body MRI was independent of lesion size, although MRI tended to detect small lesions that whole-body PET/CT missed. MRI was more accurate in eight out of nine anatomic regions. PET/CT performed slightly better in the lower spine, while both modalities had problems finding small lesions in the upper shoulder and rib cage. Four metastases that were identified with whole-body MRI in the distal femur were not observed with PET/CT because of field-of-view limitations, Schmidt said.
A 32-channel radiofrequency coil array that provided 205 cm of coverage, combined with parallel imaging acceleration, boosted performance of the 1.5T scanner, Schmidt said. T1-weighted coronal imaging was performed in five stages that were then reconstructed to produce whole-body images. Sagittal T1-weighted and short-tau inversion recovery images were also acquired during abdominal and pelvic stages. The average room time for a scan was 45 minutes.
Whole-body PET/CT involved 200 MBq of FDG. Low-dose CT for attenuation correction preceded an emission scan with a 3D reconstruction algorithm; a diagnostic CT scan in late venous phase at 130 mA/130 kVp was also performed. Time in the room averaged 103 minutes.
Despite the results, Schmidt stopped short of recommending that whole-body MRI replace FDG-PET/CT for this application.
"The two techniques are complementary, but using both brings in the matter of cost," he said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.